摘要
Objective:To study the clinical efficacy of bortezomib combined with dexamethasone in the treatment of primary multiple myeloma.Methods:Seventy patients with primary multiple myeloma treated in Shaanxi Provincial People’s Hospital between January 2020 and January 2021 were divided into two groups,a control group and a study group,using the random number table method;35 patients in the control group were treated with conventional treatment,and the other 35 patients in the study group were treated with bortezomib combined with dexamethasone.The patients’clinical outcomes,clinical indices,satisfaction,and adverse reactions were compared between the two groups.Results:There were significant differences(p<0.05)in the indices between the two groups of patients treated with different treatment modalities for primary multiple myeloma.Conclusion:The use of bortezomib combined with dexamethasone for patients with primary multiple myeloma can effectively improve the treatment outcomes,clinical indices,patient satisfaction,and adverse reactions;hence,it is worthy to be widely promoted in clinical practice.
